Broken Moats on X
$LLY has nlrp3 trials so that would just put them in the same conversation no with a head start? Agree its valuable to NVO but wouldn't the derivatives like a $BIOA get more juice of ZEUS then $NVO from validating the space. I like NVO but management shoots themselves in the foot constantly and AZN etc competition on weight loss is coming
